---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030681"
form_type: "8-K"
ticker: "CDT"
cik: "0001896212"
company_name: "CDT Equity Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:19:16.956446+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares

## Summary
- Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.
- Conduit pays $1.5M upfront and issues 9.5M shares to AstraZeneca; AstraZeneca gets sublicense revenue share.
- AstraZeneca receives right of first negotiation if Conduit seeks third-party rights to licensed compounds.
- Conduit plans to initiate Phase II trials in autoimmune disorders and idiopathic male infertility in 2024.

## SEC filing metadata
- accession: 0001493152-24-030681
- form_type: 8-K
- ticker: CDT
- cik: 0001896212
- company_name: CDT Equity Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1896212/000149315224030681/0001493152-24-030681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1896212/000149315224030681/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030681
- JSON: https://secwatch.observer/filing/0001493152-24-030681.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030681.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.